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Abstract
Objective: This study was conducted to assess the effect of combination treatment of quinine and
rabeprazole in the treatment of uncomplicated Plasmodium falciparum malaria.
Methods: The study included 50 patients of uncomplicated P. falciparum malaria. Group 1 (25
patients) received quinine and placebo (Q+P) while Group 2 (25 patients) received quinine and
rabeprazole (Q+R). Diagnosis was confirmed by peripheral blood film (PBF) and rapid diagnostic
test (RDT). Temperature was recorded every 6 h. All patients were followed-up on Days 7, 14, 21,
28  for detailed clinical and parasitological examination.
Results: A total of 20 patients in each group completed the treatment and followed-up for 28 days.
While two patients in Group 1 (Q+P) and one patient in Group 2 (Q+R) were lost in follow-up;
and seven (Q+P = 4, Q+R =3) patients were withdrawn from the study. Fever clearance time
(FCT) of the two groups was also almost similar (Group 1 : 2 = 52.8 : 51.3 h). No statistically
significant difference was observed in early treatment failure (ETF) either of the groups. None of
the patients in both the groups showed late clinical failure (LCF) or late parasitological failure
(LPF). However, there was a significant difference in the parasite clearance rates of the two groups
(p<0.05).
Conclusion: The study results suggest that addition of rabeprazole to quinine regimen resulted in
an increase in the parasite elimination rate, which may be helpful in reducing the duration of
treatment and increasing patient compliance.
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Introduction
Malaria is a protozoan disease caused by infection
with parasites of genus Plasmodium1. Five species
responsible for human infection are P. falciparum,
P. vivax, P. malariae, P. ovale and P. knowlesi (re-
cently reported in human infection). At present about
300–500 million new cases are detected each year
and 1.1 to 2.7 million deaths are reported annually,
mostly due to P. falciparum malaria1.
Quinine is one of the oldest and very useful drug for
the treatment of falciparum malaria and is effective
in uncomplicated as well as severe cases. It acts prin-
cipally on the mature trophozoite stage of parasite
development and does not prevent sequestration or
further development of circulating ring stages of P.
falciparum. It also has effect on the pre-erythrocytic
stages of malaria parasites2. To reduce the onset of
resistance and increase the patient compliance, qui-
nine is used in combination with an antibiotic, usu-
ally doxycycline, tetracycline, clindamycin or
azithromycin2. Over dosage of quinine may cause
oculotoxicity, including blindness from direct retinal
toxicity, and cardiotoxicity, which can also be fatal3.
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public health problem in many areas where malaria
is endemic, and in last few years the declining effi-
cacy of important antimalarial drugs has left us with
an increasingly limited choice of effective antima-
larial drugs4,5.
Proton pump inhibitors (PPIs) have antiparasitic and
antibacterial properties. Omeprazole inhibits the
growth of Leishmania donovani6 and is also effec-
tive against the bovine pathogen Tritrichomonas foe-
tus. PPIs also have antibacterial activity against
Helicobacter pylori and rabeprazole is the most ef-
fective amongst different PPIs.
Earlier study on the efficacy of four PPIs, viz.
omeprazole, lansoprazole, rabeprazole and
pantoprazole against P. falciparum in vitro has
shown definite action against three different isolates
of P. falciparum7. Earlier an in vitro study also found
combination of quinine and omeprazole to be sig-
nificantly synergistic8, similarly another in vitro study
found rabeprazole and lansoprazole to be the most
effective antimalarial agents amongst the available
PPI7. Thus, we decided to study its synergistic effi-
cacy in the treatment of uncomplicated falciparum
malaria.
Material & Methods
This study was conducted between July and Novem-
ber 2007 on 50 adult hospitalized patients of uncom-
plicated P. falciparum malaria. The diagnosis was
confirmed by microscopic examination of Giemsa
stained peripheral blood smear. Patients of P.
falciparum mono infection with density of 1000 –
100,000 asexual parasite/l were included in the
study. Other inclusion requirements were docu-
mented fever (axillary temperature >37.5oC) in the
past 48 h in absence of another obvious cause of fe-
ver, willing to participate in the study, willing to stay
in hospital up to one week and to come for follow-
up visits up to 28 days.
These patients were randomly divided into two
groups. They were allocated in accordance with a
randomization chart. Group 1 (25 patients) received
quinine with placebo [Q+P; Quinine (10 mg/kg bw)
8 h orally + Placebo (BD) orally for 7 days] and the
Group 2 (25 patients) received quinine with
rabeprazole [Q+R; Quinine (10 mg/kg bw) 8 hourly
orally + Rabeprazole (20 mg BD) orally] for 7 days.
Identical appearing capsule filled with inert sub-
stances were used as placebo. Patients of both the
groups received 45 mg of primaquine in a single dose
on 3rd day. Temperature was recorded every 6 h.
Laboratory investigations were performed on all pa-
tients in the beginning, and later if considered neces-
sary. Blood smears were taken six hourly till it be-
came negative for two consecutive times. Since all
patients were hospitalized, compliance was ensured.
All patients were followed on Day 7, 14, 21, 28. On
every visit a complete physical examination was done
and peripheral blood smear was studied for the evi-
dence of parasite. Patients who withdrew before re-
ceiving at least one dose of the study drugs and pa-
tients lost to follow-up after randomization, were
excluded and their records were deleted from the da-
tabase. All the end points and adverse effects were
recorded before the randomization. SPSS 12.0 soft-
ware and strata 9.0 were used for data management
and statistical analysis. For all statistical analysis
p<0.05 was considered to be statistically significant.
Results
Out of 50 patients enrolled only 40 could complete
the study. The demographic profile and symptoma-
tology of two groups were almost similar and de-
scribed in Table 1. Therapeutic response to drug regi-
men was classified as per WHO criteria. Early
treatment failure (ETF), late clinical failure (LCF),
late parasitological failure (LPF) and adequate clini-
cal response (ACR) were taken as primary outcome
measures. Fever clearance time (FCT) and parasite
clearance time (PCT) were taken as secondary out-
come measures. The details of response in two groups
are shown in Table 2. The FCT of both the groups
was almost same having 52.8 and 51.3 h and was not
statistically significant. The mean PCT of Group 1
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which was statistically significant (p <0.05) (Table
3). These were secondary outcome measures.
Discussion
Quinine is an important drug for the treatment of P.
falciparum malaria, however, the mono therapy de-
crease the selection pressure and ultimately leads to
development of resistance. Thus, quinine is used with
antibiotic like doxycycline, tetracycline or
azithromycin to overcome this phenomenon5. PPI is
another group of drugs with well-proved anti-ma-
larial activity and also helpful in overcoming com-
monly observed gastrointestinal side-effects like nau-
sea and vomiting. Rabeprazole is considered to be
the most potent PPI amongst the other commonly
available drugs9 and based on these observations we
planned this observational study to see the synergis-
tic effect of these two drugs.
The important clinical observation of this study was
evidence of ETF in three out of the 20 patients re-
ceiving Q+P, 2 out of these 3 patients had
parasitaemia on Day 2 higher than Day 0 count, irre-
spective of axillary temperature and one patient had
parasitaemia on Day 3 with axillary temperature
>37.5. ETF was not observed in any patient of Q+R
group. However, the difference was not statistically
significant. None of the patients in either group ex-
perienced LCF or LPF. The Q+P group showed 85%
ACR while the Q+R group showed 100%. However,
the difference was not statistically significant
(p >0.05), which may be because of less number of
cases.
The difference in ETF rate of the two groups can be
due to the antimalarial activity of rabeprazole or the
Table 1. Clinical characteristics of patients with
P. falciparum malaria
Characteristics Group 1 Group 2 Total
(Q+P) (Q+R)  patients
(n=20) (n=20) (n=40)
Age
Mean 26.05 35.1 30.575
SD 10.555 18.352 15.471
Sex
Male 10 16 24 (60)
Female 10 4 16 (40)
Clinical symptoms
Fever 20 20 40 (100)
Chills and Rigors 13 14 27 (67.5)
Nausea and Vomiting 14 16 30 (75)
Abdominal pain 2 4 6 (15)
Dizziness 2 3 5 (12.5)
Diarrhea 1 2 3 (7.5)
Headache 13 12 25 (62.5)
Bodyache 11 10 21 (52.5)
Parasite density in the beginning
<20,000 8 10 18 (45)
20,001 – 40,000 9 10 19 (47.5)
40,001 – 60,000 1 0 1 (2.5)
60,001 – 80,000 1 1 2 (5)
Table 2. Details of primary efficacy variables
Para- Group 1 Group 2 Total 2 p-value
meters (Q+P) (Q+R)  patients
(n=20) (n=20) (n=40)
No. (%) No. (%) No. (%)
ETF 3 (15) 0 (0) 3 (7.5) 3.243 >0.05
LCF 0 (0) 0 (0) 0 (0)
LPF 0 (0) 0 (0) 0 (0)
ACR 17 (85) 20 (100) 37 (92.5) 3.243 >0.05
ETF – Early treatment failure; LCF – Late clinical failure; LPF –
Late parasitological failure; ACR – Adequate clinical  response.
Table 3. Changes in secondary efficacy variables
Parameter Group 1 (n=20) Group 2 (n=20) t-value p-value
Mean SD SE Mean SD SE
FCT 52.8 20 4.47 51.3 16.68 3.73 –0.283 0.780
PCT 60.3 12.07 2.70 51.9 9.18 2.05 –2.424 0.026
FCT – Fever clearance time; PCT – Parasite clearance time.
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increased susceptibility of the malarial parasites to
quinine in the presence of rabeprazole. Nevertheless,
the cure rate was 100% in both the groups, suggest-
ing that even if it is due to declining susceptibility of
P. falciparum to quinine, it is still a very effective
antimalarial agent in this region, although the cure
rate may be different at different places10.
In spite of the observation of no significant differ-
ence in the cure rates of the two groups, the signifi-
cant difference in the PCT of the two groups was
evident (60.3 h vs 51.9 h, p <0.05). A study from
Thailand observed the mean PCT of patients treated
with quinine mono therapy to be 82.1 h11 whereas
another study from Vietnam reported it to be 62 h12.
This significant difference in the PCT of the two
groups can certainly be attributed to the synergistic
antimalarial activity of rabeprazole. This observation
suggests that addition of rabeprazole to quinine fa-
cilitate the parasite elimination rate, and it may be
helpful in reducing the duration of the quinine therapy,
thereby decreasing the side-effects and increasing the
patient compliance.
The PPIs are known to have antiparasitic and anti-
bacterial activities. Omeprazole inhibits Leishmania
donovani by inhibiting the P type K+H+ ATPase on
its surface membrane13. An in vitro study demon-
strated that omeprazole inhibits the growth of met-
ronidazole resistant bovine pathogen Tritrichomonas
foetus by inhibiting the enzyme Pyruvate decarboxy-
lase of the parasite14. Certain in vitro studies have
also shown a significant activity of PPIs against P.
falciparum7,15. The precise mode of action of PPIs
against P. falciparum is unknown, but they may have
mechanisms distinct from those of the conventional
drugs7. The PPIs are metabolized by hepatic CYPs
and, therefore, may interfere with the metabolism of
other drugs eliminated by this route. This effect may
cause increase in the serum quinine concentration.
PPIs may inhibit the growth of P. falciparum by in-
hibiting parasite ATPase activity, which in turn in-
creases the pH of the acidic food vacuole. There is
evidence that quinine also inhibits membrane ATPase
in the same way as PPIs16.
Another in vitro study reported the combination of
omeprazole and quinine to be significantly synergis-
tic against P. falciparum8. It was also having effec-
tive action against all of the P. falciparum clones
tested at lower concentrations than omeprazole and
pantoprazole. According to these studies for potent
activity, the drug should have both hydrogen bond
acceptor and hydrogen bond donor sites along with
two aromatic hydrophobic sites. The hydrogen bond
acceptor feature is totally absent in the mapping for
pantoprazole. We used rabeprazole because of the
fact that although all PPIs were found to be active
against H. pylori in an in vitro study but rabeprazole
had shown greater antibacterial properties against
8 strains of H. pylori than omeprazole and
lansoprazole17. It was also better found than
omeprazole and lansoprazole in inhibiting the urease
activity of H. pylori18 and suppressing the motility
of H. pylori, Campylobacter jejuni and C. coli19.
There was statistically significant difference in ETF
or ACR in the two groups, which definitely indicates
the antimalarial activity of rabeprazole. This obser-
vation is further supported by the significant differ-
ence in the PCT of the two groups. These results
strongly suggest that addition of rabeprazole to qui-
nine results in an increase in the parasite elimination
rate and it may be helpful in reducing the duration of
the quinine therapy, thereby decreasing the side-ef-
fects of quinine and increasing patient compliance.
Our results showed that a rabeprazole-quinine com-
bination could be a safe combination for Pf malaria.
Moreover, a larger study or a randomized controlled
trial can conclusively prove the antimalarial activity
of rabeprazole and its use in management of malaria.
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